Related Experiment Videos
[p16INK4/CDKN2 gene deletions and mutations in non-small cell lung cancers]
1Department of Medical Genetics, Sun Yat-sen University of Medical Sciences, Guangzhou, 510089 P. R. China.
Objective:
To investigate the genomic status of cyclindependent kinase-4 inhibitor, p16 INK4/CDKN2 gene in primary non-small cell lung cancers.
Methods:
p16 gene was analysed by duplex PCR, PCR-SSCP, and sequencing in 31 primary non-small cell lung cancer (NSCLC) tissues.
Results:
Gene deletions were found in three samples (3/31), one case had whole p16 gene deletion and the other two had deletion in exon 1 and in exon 2 respectively. Two cases of point mutations (2/30) in the gene had been found, one in exon 1 and another one in exon 2. In the 5 cases of p16 gene abnormal samples, 4 cases (two cases of deletions and two cases of mutations) were non-small cell lung cancers with lymphnode metastasis (4/20).
Conclusion:
These results indicate that inactivation of p16 gene is associated with some NSCLC (5/31), and probably be a late event in NSCLC carcinogenesis.
Insights
Inactivation of the p16 gene, a key cell cycle regulator, is linked to some non-small cell lung cancers (NSCLC). This genetic alteration may occur late in NSCLC development.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Context:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
- The p16 INK4/CDKN2 gene plays a crucial role in cell cycle regulation and is a known tumor suppressor.
- Genomic alterations in tumor suppressor genes are frequently observed in cancer development.
Purpose:
- To determine the genomic status of the p16 INK4/CDKN2 gene in primary NSCLC tissues.
- To identify specific alterations such as deletions and mutations in the p16 gene.
- To explore the association between p16 gene alterations and clinicopathological features of NSCLC.
Summary:
- Analysis of 31 primary NSCLC tissues revealed genomic alterations in the p16 gene in 5 cases (16.1%).
- Alterations included gene deletions (3/31) and point mutations (2/30) affecting different exons of the p16 gene.
- Notably, 4 out of 5 cases with p16 gene abnormalities exhibited lymph node metastasis (4/20), suggesting a potential correlation.
Impact:
- These findings suggest that p16 gene inactivation is associated with a subset of NSCLC cases.
- The observed alterations may contribute to NSCLC development, potentially as a late-stage event.
- Further research into p16 gene's role could inform diagnostic and therapeutic strategies for NSCLC.